Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer’s disease -
ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books Search …

Tacrine (1) was the first acetylcholinesterase inhibitor (AChEI) introduced in therapy for the
treatment of Alzheimer's disease (AD), but similarly to the most recent approved AChEIs and …

A series of tacrine–coumarin hybrids (8a–t) were designed, synthesized and evaluated as
multifunctional cholinesterase (ChE) inhibitors against Alzheimer's disease (AD). The …

A structural series of 7-MEOTA-adamantylamine thioureas was designed, synthesized and
evaluated as inhibitors of human acetylcholinesterase (hAChE) and human …

The number of people suffering from Alzheimer's disease (AD) is expected to increase
dramatically in the coming decades. Currently, acetylcholinesterase inhibitors (AChEis) …

2, 6-Disubstituted pyridazinone 4 was identified by HTS as a novel acetylcholinesterase
(AChE) inhibitor. Under SAR development, compound 17e stood out as displaying high …

Nitric oxide (NO)/solube GC (sGC)/cGMP signaling is important for modulating synaptic
transmission and plasticity in the hippocampus and cerebral cortex, which are critical for …

To search for multifunctional anti-Alzheimer's disease (AD) agents with good safety, the
previously synthesized tacrine–flurbiprofen hybrids 1a and 1b were modified into tacrine …

The synthesis, toxicity, neuroprotection, and human acetylcholinesterase (hAChE)/human
butyrylcholinesterase (hBuChE) inhibition properties of β-naphthotacrines 1–14 as new …

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering
from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or …